LANGUAGES
English
اردو
About Us
Company Profile
Our Vision, Mission & Values Statement
History
Message from CEO
Board of Directors
Partnerships
Products Portfolio
Pharma & OTC
Medical Technologies
Exports
Investors
Election of Directors
Investor Information
Financial Reports
Code of Conduct
Shareholder Information
List of Shareholders (Div-44)
List of shareholders (Div-45)
Compliance Certificate
Share Value Price
Rating of Company and Instruments
Investor Relations
Patients
Disease
Send Query
Physicians
CSR
Media
Awards
Membership of Industry Associations and Trade Bodies
Videos
News & Updates
Last Date of Website Updates
Careers
Peg-INF
Select Therapeutic
ANALGESICS
Anti-histamines
Anti-Obesity
ANTIBIOTICS
Antiinflammatory Analges
Antiviral
CARDIOLOGY
Central Nervous System
Dermatology
Diabetes
Expectorant
Gastroenterolog
Gastroenterology
Gastroenterology/Rheumatology
GI Health/Infectious Disease
HEPATOLOGY
Immunology
Infectious Disease
Musculoskeletal
Neurology
ONCOLOGY
UROLOGY
Select Bodyparts
Acute Coronary Syndrome
Allergies
Angina Pectoris
Anxiety
Bacterial Infections/Antibiotic
Benign Prostatic Hyperplasia (BPH)
Breast Cancer
Burns
Chemotherapy
Colorectal Cancer
Congestive Heart Failure
Cough
Diabetes
Dyslipidemia
Epilepsy
Functional Dyspepsia
Fungal Infections
GERD
GIT related Bacterial Infections and irritable bowel syndrome (IBS)
Hepatitis B
Hepatitis-C
Hypertension
IBD
Invasive Fungal infections/Antifungal
LIVER CIRRHOSIS
Male-pattern Baldness
Metabolic Syndrome
Muscle and Joint pain/Topical Analgesic
N/A
Neutropenia
NIDDM
Non opioid Analgesics (NSAIDs/COXIBs)
Peptic Ulcers
Respiratory tract infections.
Transplantation
A-Z
Z-A
Name:
Peg-INF
Company:
BF Biosciences Limited
Therapeutic Segment:
HEPATOLOGY
Area:
Hepatitis-C
Description:
Peg-INF (Pegylated Interferon Alpha 2a 180 mcg – 40KD) is available in vials containing 1 ml ready-to-inject solution. Peginterferon is part of a once-weekly regimen indicated in the treatment of chronic Hepatitis C in combination with Ribavirin.
TOP
English 
اردو 
